https://pipelinereview.com/Onward-Therapeutics-and-Biomunex-Pharmaceuticals-Enter-into-a-Worldwide-Exclusive-License-and-Co-development-Agreement-to-a-Bispecific-Antibody-for-Immuno-Oncology/